Journal: Patient education and counseling

Article Title: Deciding on breast cancer risk reduction: the role of counseling in individual decision-making – a qualitative study

doi: 10.1016/j.pec.2017.06.033

Figure Lengend Snippet: Telephone Interview Summary Sheet for participants who decided about SERM use

Article Snippet: Health care provider (HCP) recommendation and selective estrogen receptor modulator (SERM) choice: NSABP DMP-1 video component substudy 3.2.

Techniques:

Journal: Patient education and counseling

Article Title: Deciding on breast cancer risk reduction: the role of counseling in individual decision-making – a qualitative study

doi: 10.1016/j.pec.2017.06.033

Figure Lengend Snippet: Eligibility Criteria

Article Snippet: Health care provider (HCP) recommendation and selective estrogen receptor modulator (SERM) choice: NSABP DMP-1 video component substudy 3.2.

Techniques: In Situ

Journal: Patient education and counseling

Article Title: Deciding on breast cancer risk reduction: the role of counseling in individual decision-making – a qualitative study

doi: 10.1016/j.pec.2017.06.033

Figure Lengend Snippet: Health care provider (HCP) recommendation and selective estrogen receptor modulator (SERM) choice: NSABP DMP-1 video component substudy

Article Snippet: Health care provider (HCP) recommendation and selective estrogen receptor modulator (SERM) choice: NSABP DMP-1 video component substudy 3.2.

Techniques:

Journal: Patient education and counseling

Article Title: Deciding on breast cancer risk reduction: the role of counseling in individual decision-making – a qualitative study

doi: 10.1016/j.pec.2017.06.033

Figure Lengend Snippet: Themes of decision-making including quotations

Article Snippet: Health care provider (HCP) recommendation and selective estrogen receptor modulator (SERM) choice: NSABP DMP-1 video component substudy 3.2.

Techniques: Control, Biomarker Discovery

Journal: The Journal of Neuroscience

Article Title: Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors

doi: 10.1523/JNEUROSCI.1530-18.2019

Figure Lengend Snippet: Several candidate SERMs promote OPC differentiation and have translational potential. a, Graph representing the percentage of micropillars wrapped following the repetition of the original binary indicant for myelination using micropillar arrays (BIMA) screen using a novel, curated list of candidate SERMs. This graph represents the quantification of the number of micropillars wrapped by either OPCs (PDGFRα) or oligodendrocytes (MBP). b, Summary of all SERMs tested, their previously reported mechanism of action, their FDA approval status, and their effects on OPC differentiation. Error bars indicate SEM. **p < 0.01, ***p < 0.001. For all experiments, n = 2 temporally separate trials; n = 2 microarrays per group per trial.

Article Snippet: These results led us to concentrate on one candidate SERM: BZA, a nonsteroidal, third-generation European Medicines Agency (EMA)-approved SERM (Wyeth Europa, Ltd., Conbriza [package insert], 2009), which in combination with conjugated estrogens is FDA approved in menopausal women (Wyeth Pharmaceuticals, Inc., and Pfizer, Inc.: Duavee [package insert], 2013; Mirkin and Komm, 2013 ).

Techniques:

Journal: The Journal of Neuroscience

Article Title: Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors

doi: 10.1523/JNEUROSCI.1530-18.2019

Figure Lengend Snippet: BZA enhances OPC differentiation in vitro. a, Representative images of control and BZA-treated (500 nm) cultures of human OPCs treated for 5 d before immunostaining for O4 (red) and MBP (green). b, Quantification of MBP+ cells over total O4+ cells. c, Representative images of rat OPC cultures and cultures treated with BZA at 5, 10, 20, 50, or 500 nm or vehicle control for 2 d and immunostained for MBP (red) and PDGFRα (green; an OPC marker). Cell nuclei are shown by DAPI (blue). d, Quantification of MBP+ cells over total cells (DAPI+ nuclei) for control cultures and 5–500 nm BZA. e, Quantification of fold-change of MBP+ cells over total cells (DAPI+ nuclei) for control cultures and additional candidate SERMs as well as estriol at 500 nm. f, Representative images of control and BZA-treated (500 nm) OPC/DRG cocultures immunostained for MBP (red), CC1 (white), and PDGFRα (green). Cell nuclei are shown by DAPI (blue). g, Quantification of CC1 and MBP colabeled cells per square millimeter. h, Representative images displaying CASPR staining clustered in the paranodal region of myelin sheaths in BZA-treated cocultures. i, Quantification of internodes per square millimeter in vehicle- and BZA-treated groups. Error bars indicate SEM. *p < 0.05, ***p < 0.001. For all experiments, n = 2 temporally separate trials; n > 3 coverslips per group per trial.

Article Snippet: These results led us to concentrate on one candidate SERM: BZA, a nonsteroidal, third-generation European Medicines Agency (EMA)-approved SERM (Wyeth Europa, Ltd., Conbriza [package insert], 2009), which in combination with conjugated estrogens is FDA approved in menopausal women (Wyeth Pharmaceuticals, Inc., and Pfizer, Inc.: Duavee [package insert], 2013; Mirkin and Komm, 2013 ).

Techniques: In Vitro, Control, Immunostaining, Marker, Staining

Journal: The Journal of Neuroscience

Article Title: Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors

doi: 10.1523/JNEUROSCI.1530-18.2019

Figure Lengend Snippet: BZA enhances OPC differentiation independently of the ER a, Representative images of control and BZA-treated (500 nm) WT, ERα, and ERβ KO OPCs, treated for 2 d and immunostained for MBP (red) and PDGFRα (green). Cell nuclei are shown by DAPI (blue). b, Quantification of MBP+ cells over total cells in WT, ERα, and ERβ KO OPC cultures treated with control or BZA (500 nm). c, Quantification of MBP+ cells over total cells in ERα and ERβ KO OPC cultures treated with various SERMs (500 nm), as well as the positive control T3 (1×). d, Representative images of control and BZA-treated (500 nm) OPCs from ERα and ERβ DKO animals treated for 2 d and immunostained for MBP (red) and PDGFRα (green). Cell nuclei are shown by DAPI (blue). e, Quantification of MBP+ cells over total cells (DAPI+ nuclei) in ER-DKO OPC cultures of BZA- and tamoxifen (500 nm)-treated groups. For all quantifications, error bars indicate SEM. *p < 0.05, ***p < 0.001. For all experiments, n = 3 temporally separate trials and n > 3 coverslips per group per trial.

Article Snippet: These results led us to concentrate on one candidate SERM: BZA, a nonsteroidal, third-generation European Medicines Agency (EMA)-approved SERM (Wyeth Europa, Ltd., Conbriza [package insert], 2009), which in combination with conjugated estrogens is FDA approved in menopausal women (Wyeth Pharmaceuticals, Inc., and Pfizer, Inc.: Duavee [package insert], 2013; Mirkin and Komm, 2013 ).

Techniques: Control, Positive Control

Journal: The Journal of Neuroscience

Article Title: Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors

doi: 10.1523/JNEUROSCI.1530-18.2019

Figure Lengend Snippet: Bioinformatics profiling implicates set of candidate targets positing unique pathway for SERMs a, Network of first-degree (genes/proteins; green squares) and second-degree (diseases; yellow squares) neighbors of select FDA-approved pro-remyelinating and non-remyelinating compounds (blue squares) was generated using HetioNet (Himmelstein et al., 2017) and visualized using iCTNET (Wang et al., 2015). b, Ggenes with the highest number of connections to the four pro-remyelinating compounds are labeled and the resulting subnetwork is enlarged in the inset. EBP is the predicted binding partner of pro-remyelinating compounds (raloxifene and tamoxifen) based on recently published data. ST6GALNAC2, SPP1, MSMO, and FDPS are upregulated and RRP12 is downregulated by all four compounds. Binding data were retrieved from BindingDB, DrugBank, and DrugCentral. Only binding relationships to single proteins with affinities of at least 1 μm (as determined by Kd, Ki, or IC50) were selected from the October 2015 release of BindingDB. Target, carrier, transporter, and enzyme interactions with single proteins (i.e., excluding protein groups) were extracted from DrugBank 4.2. Regulatory effects of compounds on genes was based on the LINCS L1000 dataset and computed as in Himmelstein et al. (2017). Key terms: “Binding” indicates physical evidence that compound binds protein used to map drugs onto proteins; “association” indicates statistical evidence that gene confers risk to the disease and is used to map genes onto diseases. c, Representative images of control, BZA-treated (500 nm), clemastine-treated (500 nm), and BZA + clemastine-treated (500 nm, 500 nm) OPCs treated for 2 d and immunostained for MBP (red) and PDGFRα (green). Cell nuclei are shown by DAPI (blue). d, Quantification of MBP+ cells over total cells (DAPI+ nuclei) in OPC cultures of BZA-treated, clemastine-treated, and BZA + clemastine-treated (500 nm) groups. For all quantifications, error bars indicate SEM. *p < 0.05, ***p < 0.001. For all experiments, n = 4 temporally separate trials and n > 3 coverslips per group per trial.

Article Snippet: These results led us to concentrate on one candidate SERM: BZA, a nonsteroidal, third-generation European Medicines Agency (EMA)-approved SERM (Wyeth Europa, Ltd., Conbriza [package insert], 2009), which in combination with conjugated estrogens is FDA approved in menopausal women (Wyeth Pharmaceuticals, Inc., and Pfizer, Inc.: Duavee [package insert], 2013; Mirkin and Komm, 2013 ).

Techniques: Generated, Labeling, Binding Assay, Control